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Abstract
Biliary acute pancreatitis (AP) is a serious condition, which currently has no speciﬁc treatment. Taurolithocholic acid
3-sulfate (TLC-S) is one of the most potent bile acids causing cytosolic Ca2+ overload in pancreatic acinar cells (PACs),
which results in premature activation of digestive enzymes and necrosis, hallmarks of AP. The inositol 1,4,5-
trisphosphate receptor (IP3R) and the ryanodine receptor (RyR) play major roles in intracellular Ca
2+ signaling.
Inhibition of these endoplasmic reticulum-located channels suppresses TLC-S-induced Ca2+ release and necrosis,
decreasing the severity of AP. Anti-apoptotic B-cell lymphoma (Bcl)-2-family members, such as Bcl-2 and Bcl-XL, have
emerged as important modulators of IP3Rs and RyRs. These proteins contain four Bcl-2 homology (BH) domains of
which the N-terminal BH4 domain exerts critical roles in regulating intracellular Ca2+ release channels. The BH4
domain of Bcl-2, but not of Bcl-XL, binds to and inhibits IP3Rs, whereas both BH4 domains inhibit RyRs. Although clear
cytoprotective effects have been reported for these BH4 domains, it remains unclear whether they are capable of
inhibiting pathological Ca2+-overload, associated with AP. Here we demonstrate in PACs that the BH4 domains of Bcl-
2 and Bcl-XL inhibit RyR activity in response to the physiological agonist cholecystokinin. In addition, these BH4
domains inhibit pathophysiological TLC-S-induced Ca2+ overload in PACs via RyR inhibition, which in turn protects
these cells from TLC-S-induced necrosis. This study shows for the ﬁrst time the therapeutic potential of BH4 domain
function by inhibiting pathological RyR-mediated Ca2+ release and necrosis, events that trigger AP.
Introduction
The anti-apoptotic B-cell lymphoma 2 (Bcl-2)-family
members, like Bcl-2 and Bcl-XL, are critically involved in
maintaining mitochondrial integrity by scavenging and
inhibiting pro-apoptotic Bcl-2-family members, such as
Bax and Bak1. This interaction occurs via the hydrophobic
cleft, formed by the Bcl-2 homology (BH) domain 1, 2,
and 3, of anti-apoptotic Bcl-2 proteins and the BH3
domain of the pro-apoptotic family members. In addition
to the hydrophobic cleft the last most N-terminal BH
domain, the BH4 domain, is also critical for the anti-
apoptotic properties of Bcl-22–4.
Besides neutralizing pro-apoptotic Bcl-2-family mem-
bers, anti-apoptotic Bcl-2 proteins also emerged as critical
modulators of intracellular Ca2+ signaling5–7. In parti-
cular, Bcl-2 is present at the membranes of the endo-
plasmic reticulum (ER), the main intracellular Ca2
+-store8,9. At the ER, Bcl-2 directly inhibits the inositol
1,4,5-trisphosphate (IP3) receptor (IP3R)
3,4, a ubiquitously
expressed IP3-gated ER-located Ca
2+ release channel10.
Bcl-2 forms a protein complex with the IP3R by targeting
the central modulatory domain of the channel. As such,
Bcl-2 limits excessive Ca2+-release that may trigger
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apoptotic cell death. Importantly, the BH4 domain of Bcl-
2 by itself is sufﬁcient for inhibiting IP3R-mediated Ca
2+
release, protecting cells against Ca2+-induced mitochon-
drial outer membrane permeabilisation (MOMP) and
subsequent apoptosis3. Although, the BH4 domain of Bcl-
2 and that of Bcl-XL are very similar in size, sequence and
structure, the latter is unable to bind to and inhibit IP3R-
mediated Ca2+ release2. The difference in IP3R-inhibitory
properties between the BH4 domain of Bcl-2 and Bcl-XL
could be largely attributed to a single amino acid change.
Substituting Lys17 for an Asp residue in the BH4 domain
of Bcl-2 abrogated its IP3R-inhibitory function, while
changing Asp11 into a Lys residue in BH4 domain of Bcl-
XL enhanced its IP3R-inhibitory function
2.
In addition to the IP3R, we recently showed that anti-
apoptotic Bcl-2 proteins also bind to and inhibit ryano-
dine receptors (RyR)7,11. RyRs form a second class of the
ER-located Ca2+ release channels, mainly expressed in
specialized tissues such as the heart, brain, muscle, but
also in the pancreas12,13. In these tissues, RyR-mediated
Ca2+ release is involved in muscle contraction, memory
formation and secretion of digestive enzymes13,14. Endo-
genous activation of RyRs occurs via Ca2+-induced Ca2+
release or via NAADP and/or cyclic-ADP ribose pro-
duction15. The interaction between RyRs and Bcl-2 is
mediated by the BH4 domain of the latter. Binding of the
BH4 domain of Bcl-2 to the RyR is sufﬁcient for inhibiting
RyR-mediated Ca2+ release7. In contrast to what was
shown for the IP3R, the BH4 domain of Bcl-XL also binds
to and inhibits RyRs11. In our previous work, we
demonstrated that Bcl-2 and Bcl-XL (via their BH4
domains) could modulate pharmacological activation of
RyRs by caffeine7,11. However, prior to the present study it
was unclear whether RyR responses to physiological
agonists can also be regulated by the BH4 domains.
Furthermore, excessive RyR-mediated Ca2+ release is
linked to several pathologies and is a hallmark for the
onset of several diseases of the brain, heart, muscle, and
pancreas, such as Alzheimer’s disease, catecholaminergic
polymorphic ventricular tachycardia, malignant hyper-
thermia, and acute pancreatitis (AP), respectively13,16. The
BH4 domains of Bcl-2 proteins, particularly Bcl-XL, have
been shown to have protective anti-apoptotic effects in
several of these tissues17–21. However, a link between cell
protection and RyR inhibition by these BH4 domains has
not yet been reported. Therefore, it remains unknown
whether the BH4 domains of Bcl-2 and Bcl-XL could be
exploited as inhibitors of RyRs in diseases associated with
excessive RyR activity in order to dampen disease burden.
To address this, we have chosen pancreatic acinar cells
(PACs), in which physiological and pathophysiological
intracellular Ca2+ signaling has been extensively studied22–26.
Importantly, in PACs physiologically relevant agonists can be
utilized to trigger IP3R or RyR-dependent Ca
2+ releases,
allowing to compare the effects of the BH4 domain peptides
on both channels26. Exposing PACs to low nanomolar con-
centrations of acetylcholine (ACh) is known to trigger pri-
marily IP3R-mediated Ca
2+ oscillations via activation of
phospholipase C leading to IP3 production. In contrast,
cholecystokinin (CCK) mainly triggers RyR-mediated Ca2+
release via the production of NAADP and/or cyclic-ADP
ribose26. Finally, bile acids, such as taurolithocholic acid 3-
sulfate (TLC-S), induce IP3R and RyR-mediated Ca
2+ over-
load22, leading to premature activation of digestive enzymes
and subsequent necrosis, which is an initiating event for
AP26. It has been demonstrated that noxious Ca2+ signals
induced by TLC-S can be reduced by inhibition of IP3Rs or
RyRs, using caffeine or dantrolene, respectively24,25. Impor-
tantly, these approaches not only protected PACs against
necrosis but also ameliorated the severity of AP in mouse
models. Although it is well known that intracellular Ca2+
signaling plays important roles in the development of AP,
currently no effective treatment exists for this disease. Here,
we test whether the BH4 domains of Bcl-2/Bcl-XL proteins
can be utilized to suppress IP3R or RyR hyperactivity asso-
ciated with the onset of AP.
In this study, by employing primary isolated mouse
PACs, we show that peptides derived from the BH4
domains of Bcl-2 and Bcl-XL inhibit both physiological
and pathophysiological RyR-mediated Ca2+ release, as well
as protect PACs from TLC-S-induced necrosis. These
ﬁndings show for the ﬁrst time that the BH4 domains of
Bcl-2 and Bcl-XL can be applied as innovative peptide tools
to limit excessive RyR-mediated Ca2+ release associated
with the pathology of AP. As such, BH4-domain-based
molecules and mimetics may originate a novel group of
therapeutics with the potential application in diseases
associated with excessive Ca2+ release.
Results
The BH4 domains of Bcl-2 and Bcl-XL inhibit RyR-mediated
Ca2+ release in PACs
In the ﬁrst set of experiments, we aimed to assess the
ability of the BH4 domains of Bcl-2 and Bcl-XL to inhibit
IP3R or RyR-mediated Ca
2+ release in isolated PACs. IP3R
or RyR-mediated Ca2+ release was triggered by the phy-
siological activators ACh or CCK, respectively. The
sequences used to design the peptides corresponding to
the BH4 domain of Bcl-2 and Bcl-XL with their predicted
α-helical properties is depicted in Fig. 1a. In PACs, low
nanomolar concentrations of ACh and low picomolar
concentrations of CCK generate long lasting Ca2+ oscil-
lations, which vary in terms of amplitude and frequency
between the cells. Therefore, in single PAC, we compared
and quantiﬁed the Ca2+ oscillations induced by each
agonist before and after addition of the BH4 domain
peptides or a control peptide. We ﬁrst assessed the effects
of the BH4 domains of Bcl-2 and Bcl-XL on CCK-
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Fig. 1 The BH4 domains of Bcl-2 and Bcl-XL inhibit RyR-mediated Ca
2+ release in PACs. a Linear representation of the Bcl-2/Bcl-XL protein together
with the sequences used to design the BH4 domain peptides originating from Bcl-2 and Bcl-XL and the predicted secondary structure using the PSIPRED
secondary structure predictor (http://bioinf.cs.ucl.ac.uk/psipred/). b–d Typical traces of the Fluo-4AM single-cell Ca2+measurements performed in mouse
PACs. At the start of each experiment cells were perfused with NaHEPES containing DMSO (vehicle). After establishing the baseline (200 s), CCK (5 pM)
was added and RyR-mediated Ca2+ oscillations were measured for 5min. Then, 50 µM of either the control peptide (b), the BH4 domain of Bcl-2 (c), or
the BH4 domain of Bcl-XL (d) were added for 10min, in the continuous presence of 5 pM CCK. e Quantiﬁcation of the experiments: The area under the
curve per second (AUC/sec) of the CCK-induced Ca2+ release after peptide addition (10 min recording) was compared to the AUC/sec before peptide
addition (5min recording). Each data point represents the measurement of an individual cell. The average values ± SEM are shown (P-value <0.0001). At
least three independent experiments were performed per condition (N ≥ 3). For each condition at least 35 cells were recorded
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induced-RyR-mediated Ca2+ release (representative traces
shown in Fig. 1b–d). Ca2+ oscillations were evoked by 5
pM CCK and recorded for 5 min. Then 50 µM control
peptide (Fig. 1b), the BH4 domain of Bcl-2 (Fig. 1c) or the
BH4 domain of Bcl-XL (Fig. 1d) was added and Ca
2+
responses were measured for another 10min, in the
continuous presence of CCK. Quantitative analysis of the
responses was performed by comparing the area under
the curve (AUC). These values were further divided by the
length of the recording before (5 min) and after (10 min)
addition of the peptides, resulting in the response area
normalized per unit of time (AUC/sec). These experi-
ments show that the BH4 domains of Bcl-2 and Bcl-XL
dampen RyR-mediated Ca2+ oscillations evoked by the
physiological stimulus CCK (Fig. 1e) and are in line with
our previous ﬁndings in dissociated hippocampal neurons
and RyR-overexpression models7,11. In addition, this also
indicates that the BH4 domain peptides are taken up by
the PACs and are capable of inhibiting physiological RyR-
mediated Ca2+ release.
The BH4 domain of Bcl-2 does not inhibit IP3R-induced Ca
2
+release in PACs
Next, we assessed the effects of the BH4 domain
peptides on IP3R-mediated Ca
2+ release. Analogical to
CCK experiments single-cell Ca2+ measurements were
performed using ACh (75 nM) in order to trigger IP3R-
mediated Ca2+ oscillations (Fig. 2). As expected, sub-
sequent addition of the control peptide or the BH4
domain of Bcl-XL did not result in an inhibition of ACh-
Fig. 2 The BH4 domain of Bcl-2 does not inhibit IP3R-induced Ca
2+ release in PACs. a–c Typical traces of the Fluo-4AM single-cell Ca2+
measurements performed in mouse PACs. At the start of each experiment cells were perfused with NaHEPES containing DMSO (vehicle). After
establishing the baseline (200 s), ACh (75 nM) was added and IP3R-mediated oscillations were measured for 5 min. Then, 50 µM of either the control
peptide (a), the BH4 domain of Bcl-2 (b), or the BH4 domain of Bcl-XL (c) were added for 10 min, in the continuous presence of 75 nM ACh. d
Quantiﬁcation of the experiments: The area under the curve per second (AUC/sec) of the ACh-induced Ca2+ release after peptide addition (10 min
recording) was compared to the AUC/sec before peptide addition (5 min recording). Each data point represents the measurement of an individual
cell. The average values ± SEM are shown (P-value 0.3467). At least three independent experiments were performed per condition (N ≥ 3). For each
condition at least 14 cells were recorded
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induced-IP3R-mediated Ca
2+ release (Fig. 2a, c, d). Sur-
prisingly, also the BH4 domain of Bcl-2 was unable to
inhibit IP3R-mediated Ca
2+ release in PACs (Fig. 2b, d).
These results differ compared to what we showed pre-
viously in cultured or permeabilized cells where the BH4
domain of Bcl-2 inhibited IP3R-mediated Ca
2+ release via
its BH4 domain4,27–29.
The BH4 domain of Bcl-2 inhibits IP3R-mediated Ca
2+
release in Bcl-2 knock out PACs
The lack of inhibition of IP3R-mediated Ca
2+ release
upon application of the BH4 domain of Bcl-2 could be
due to the fact that endogenous Bcl-2 in wild-type (WT)
PACs is already associated with IP3Rs, preventing its
regulation by exogenously added BH4 domain of Bcl-2.
To address this, we performed single-cell Ca2+ measure-
ments in PACs isolated from Bcl-2 knock out (KO) mice,
devoid of endogenous Bcl-2.
In order to obtain repeatable, long lasting Ca2+ oscil-
lations in Bcl-2 KO PACs, similar in frequency and
amplitude to those evoked in WT PACs, high-nanomolar
concentrations (200 nM) of ACh were required. Con-
sistent with our previous ﬁndings, addition of 50 µM
control peptide or the BH4 domain of Bcl-XL (Fig. 3a, c, d)
did not alter IP3R-mediated Ca
2+ releases. However, in
Bcl-2 KO PACs, the BH4 domain of Bcl-2 does sig-
niﬁcantly inhibit ACh-induced-IP3R-mediated Ca
2+
release (Fig. 3b, d) compared to control peptide or the
BH4 domain of Bcl-XL.
Fig. 3 The BH4 domain of Bcl-2 inhibits IP3R-mediated Ca
2+ release in Bcl-2 KO PACs. a–c Typical traces of the Fluo-4AM single-cell Ca2+
measurements performed in Bcl-2 KO mouse PACs. At the start of each experiment cells were perfused with NaHEPES containing DMSO (vehicle,
Fig. 3a). After establishing the baseline (200 s), ACh (200 nM) was added and IP3R-mediated Ca
2+ oscillations were measured for 5 min. Then, 50 µM of
either the control peptide (a), the BH4 domain of Bcl-2 (b) or the BH4 domain of Bcl-XL (c) were added for 10 min, in the continuous presence of 200
nM ACh. d Quantiﬁcation of the experiments: The area under the curve per second (AUC/sec) of the ACh-induced Ca2+ release after peptide addition
(10 min recording) was compared to the AUC/sec before peptide addition (5 min recording). Each data point represents the measurement of an
individual cell. The average values ± SEM are shown (P-value <0.0001). At least three independent experiments were performed per condition (N ≥ 3).
For each condition at least 35 cells were recorded
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The inhibitory properties of the BH4 domain peptides
were also tested on CCK-evoked oscillations in Bcl-2 KO
PACs (Fig. 4a–d). In the Bcl-2 KO PACs, both the BH4
domains of Bcl-2 and Bcl-XL showed a similar response
inhibition (±50% AUC/sec) as seen in the WT PACs.
Comparing WT to Bcl-2 KO PACs (Figs. 1, 4) shows that
the BH4 domains did not confer additional inhibition of
CCK-induced Ca2+ release in the absence of Bcl-2. Taken
together these functional experiments suggest that in WT
PACs endogenous Bcl-2 mainly occupies/regulates IP3Rs
and to a lesser extent RyRs. This potentially leaves more
RyR channels available for binding to exogenously added
BH4 domain of Bcl-2, resulting in efﬁcient inhibition of
RyRs but not IP3Rs in WT PACs. Of note, just like in the
experiments utilizing ACh in Bcl-2 KO PACs (Fig. 3),
higher concentrations of CCK (10 pM) were needed to
trigger RyR-mediated Ca2+ oscillations of comparable
frequency and amplitude to those recorded in WT PACs
(Fig. 4).
The BH4 domains of Bcl-2 and Bcl-XL inhibit pathological
TLC-S induced Ca2+ releases in PACs
Combining the above results from ACh and CCK-
induced Ca2+ release, we can conclude that in WT PACs
Fig. 4 The BH4 domains of Bcl-2 and Bcl-XL inhibit RyR-mediated Ca
2+ release in Bcl-2 KO PACs. a–c Typical traces of the Fluo-4AM single-cell
Ca2+ measurements performed in Bcl-2 KO mouse PACs. At the start of each experiment cells were perfused with NaHEPES containing DMSO
(vehicle). After establishing the baseline (200 s), CCK (10 pM) was added and RyR-mediated Ca2+ oscillations were measured for 5 min. Then, 50 µM of
either the control peptide (a), the BH4 domain of Bcl-2 (b), or the BH4 domain of Bcl-XL (c) were added for 10 min, in the continuous presence of 10
pM CCK. d Quantiﬁcation of the experiments: The area under the curve per second (AUC/sec) of the CCK-induced Ca2+ release after peptide addition
(10 min recording) was compared to the AUC/sec before peptide addition (5 min recording). Each data point represents the measurement of an
individual cell. The average values ± SEM are shown (P-value <0.0001). At least three independent experiments were performed per condition (N ≥ 3).
For each condition at least 40 cells were recorded
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the inhibitory effects of the BH4 domains of Bcl-2 and
Bcl-XL on Ca
2+ release from the ER is due to the inhi-
bition of RyR- but not IP3R-mediated Ca
2+ release. This
has prompted us to investigate whether the BH4 domains
of Bcl-2 and Bcl-XL could also suppress pathological RyR-
mediated Ca2+ releases.
The bile acid TLC-S has been described to mediate
excessive, pathological intracellular Ca2+ release in PACs
and both IP3Rs and RyRs have been proposed to be
involved in this process22. Here we aimed to test whether
the BH4 domains of Bcl-2 and Bcl-XL could also inhibit
pathophysiological TLC-S-induced Ca2+ release (Fig. 5).
WT PACs were pre-treated for 5 min with either DMSO
(vehicle) or 50 µM of the peptides, then TLC-S (200 µM)
was added and Ca2+ responses were measured (Fig. 5a).
Detailed comparison of the response areas recorded for
the individual cells (AUC) per unit of time (AUC/sec)
revealed that both BH4 domains inhibited pathological
TLC-S-induced Ca2+ responses compared to the
control peptide and DMSO vehicle (Fig. 5b). Both BH4
domains inhibit RyR but not IP3R-mediated Ca
2+ release
(Figs. 1, 2) and similarly suppress TLC-S-induced Ca2+
release in WT PACs (Fig. 5a, b). Collectively, these data
indicate that the BH4 domains suppress pathophysiolo-
gical Ca2+ signaling by acting as modulators of the
excessive RyR activity.
The BH4 domains of Bcl-2 and Bcl-XL inhibit TLC-S-induced
necrosis in PACs by inhibiting excessive RyR activity
It has been well established that TLC-S-induced Ca2+
release in PACs leads to necrosis which is an underlying
cause of AP23. In addition, pharmacological inhibition of
either RyRs or IP3Rs, using dantrolene or caffeine,
respectively, not only attenuated TLC-S-induced necrosis,
but also reduced the severity of AP evoked in mouse
models of this disease24,25.
Since the BH4 domains of Bcl-2 and Bcl-XL proved to be
the effective inhibitors of TLC-S-induced Ca2+ release via
inhibiting RyRs (Fig. 5a, b), we aimed to determine whe-
ther these peptides could protect PACs against the cyto-
toxic effects of TLC-S. In the PACs, 50 µM BH4 domain of
Bcl-2 or Bcl-XL almost completely inhibited necrotic cell
death induced by 2 h treatment with 200 µM TLC-S,
compared to the control peptide or the vehicle control
(Fig. 5c and S1). This demonstrates a proof-of-principle
that the BH4 domains of Bcl-2 and Bcl-XL could be
applied as a basis for developing therapeutic tools to
decrease the necrotic burden of bile acids on PACs by
preventing the excessive RyR-mediated Ca2+ release.
Discussion
The main conclusions of this paper are that (i) the BH4
domains of Bcl-2 and Bcl-XL suppress physiological RyR-
Fig. 5 The BH4 domains of Bcl-2 and Bcl-XL inhibit pathological TLC-S-induced Ca
2+ release and necrosis in PACs by inhibiting RyR
activity. a Average traces of Fluo-4AM single-cell Ca2+ measurements performed in PACs. The cells were pre-treated for 5 min with either DMSO
(vehicle; red) or 50 µM of the peptides: control (blue), the BH4 domain of Bcl-2 (black), and the BH4 domain of Bcl-XL (pink). Then, TLC-S (200 µM) was
added and pathological intracellular Ca2+ release was measured for 5 min, in the continuous presence of either vehicle or the peptides. Average
traces ± SEM of all performed experiments are shown. b Quantiﬁcation of the experiments: Analysis of area under the curve per second (AUC/sec) of
the TLC-S-induced Ca2+ releases, in the presence or absence of the BH4 domains or control peptide. Each data point represents the measurement of
an individual cell, and the average values ± SEM are shown (P-value <0.0001). At least three independent experiments were performed per condition
(N ≥ 3). For each condition at least 35 cells were recorded. c Quantiﬁcation of the necrosis assay: Isolated PACs were treated with DMSO (vehicle) or
50 µM of the indicated peptides. 15 min later, TLC-S was added (200 µM ﬁnal concentration) to induce necrotic cell death. Propidium iodide staining
(necrosis indicator) was assessed 2 h after TLC-S addition. The negative control was treated with DMSO (vehicle) only. In each experimental repeat (N
= 4) at least 15 images were taken per treatment group (n ≥ 100 cells/treatment/experiment). The percentages of propidium iodide-positive necrotic
cells were assessed for each experimental condition. Each data point represents an independent repeat of the experiment, and the average values ±
SEM are shown (P-values <0.001)
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mediated Ca2+ release in isolated PACs exposed to the
hormone CCK; (ii) the Ca2+-signaling-inhibitory prop-
erties of these BH4 domains can be utilized to dampen
pathophysiological RyR-mediated cytosolic Ca2+ over-
load associated with AP, protecting PACs against
necrosis. Furthermore, these results indicate for the ﬁrst
time a potential for the therapeutic application of BH4
domains, or therapeutic tools derived from them, as
suppressors of (excessive) RyR-mediated Ca2+ release in
the treatment of AP.
In our previous work, we have already shown that Bcl-2,
Bcl-XL and the BH4 domains of these proteins inhibit
RyR-mediated Ca2+ release7,11. In those studies, RyR-
overexpression models and dissociated hippocampal
neurons were investigated and RyR activation was
attained pharmacologically using caffeine. In this study,
we provide evidence that the BH4 domains of Bcl-2 and
Bcl-XL inhibit RyR activity triggered by the hormone CCK
in a physiologically relevant concentration (5 pM) (Fig. 1).
Therefore, in PACs the BH4 domains of Bcl-2 and Bcl-XL
may serve as the modulators of RyR-mediated Ca2+
signals.
The lack of inhibition of IP3R-mediated Ca
2+ release in
WT PACs by the BH4 domain of Bcl-2 was somewhat
surprising (Fig. 2). However, this might be due to several
factors. First, in most of the previous studies, the peptides
were either loaded into the cells via electroporation or
were added to already permeabilized cells2,4,28. Here, the
BH4 domain peptides were added directly to intact cells
without any adjuvant approach. This, however, could limit
the intracellular concentration of the peptides and pre-
vent it from reaching the levels required for inhibiting
IP3Rs. Another possible explanation of these ﬁndings may
be related to the proteolytic activation of the digestive
enzymes and degradation of the BH4 domain of Bcl-2 or
Bcl-XL into smaller fragments, capable of inhibiting RyRs
but not IP3Rs. Although our experiments were performed
in the presence of an extracellular protease inhibitor
(inhibiting trypsin and chymotrypsin), we cannot fully
rule out the possibility of enzymatic degradation of the
BH4 domains. Finally, we hypothesize that IP3Rs in the
WT PACs may already be associated with endogenous
Bcl-2 and thus application of the BH4 domain of Bcl-2
may not provide any additional inhibition. To investigate
this, we performed control experiments using PACs iso-
lated from Bcl-2 KO mice. Importantly, in the cells
lacking endogenous Bcl-2, the exogenous BH4 domain of
Bcl-2 was capable of inhibiting ACh-induced IP3R-
mediated Ca2+ release (Fig. 3). Also in the Bcl-2 KO
PACs, no additional inhibition of CCK-induced-RyR-
mediated Ca2+ release by either BH4 domain was detec-
ted compared to the WT PACs (Figs. 1 and 4), suggesting
that in WT PACs RyRs are not heavily regulated by
endogenous Bcl-2. Collectively, these results support the
hypothesis that in WT PACs endogenous Bcl-2 may be
associated mainly with IP3Rs, limiting the potential of the
exogenously added BH4 domain of Bcl-2 to inhibit IP3R-
mediated Ca2+ release.
We also want to highlight that higher concentrations of
ACh (200 nM) or CCK (10 pM) were needed in Bcl-2 KO
PACs compared to wild-type PACs to evoke IP3R- or
RyR-mediated Ca2+ oscillations, respectively (Figs. 3 and
4). Since Bcl-2 is an inhibitor of both IP3Rs and RyRs, it is
anticipated that Bcl-2 KO PACs should be more sensitive
to ACh and CCK. It remains unclear whether in Bcl-2 KO
PACs this phenomenon occurs due to the compensatory
mechanisms or other adaptive processes during pan-
creatic development. It is possible that lack of Bcl-2 in
PACs results in reduced expression of ACh and CCK
receptors, declined levels of the proteins involved in
generation of IP3, NAADP, cADP-ribose, or decreased
levels of IP3Rs and RyRs. It is also important to note that,
compared to the WT mice, the Bcl-2 KO mice suffer
from growth retardation, facial malformation and devel-
opment of polycystic kidney disease30. Also, the pan-
creata of these Bcl-2 KO mice are much smaller
compared to the WT pancreata. Thus, this phenotypic
difference may account for the apparent reduced
responsiveness of Bcl-2 KO mouse PACs towards extra-
cellular agonists.
Bile acids, such as TLC-S, are well known to induce
pathological Ca2+ release in PACs, leading to extensive
tissue necrosis and development of AP23. The involve-
ment of both IP3R- and RyR-mediated Ca
2+ release in this
process has been previously demonstrated22. From our
previous work, we already knew that the BH4 domain of
Bcl-XL does not inhibit IP3R-mediated Ca
2+ release2. In
the present study, we conﬁrmed that observation in PACs
(Fig. 2). We also demonstrated that the BH4 domain of
Bcl-2 inhibits IP3R-mediated Ca
2+ release in Bcl-2 KO but
not in WT PACs (Figs. 2, 3). In addition, we show that
both the BH4 domains of Bcl-2 and Bcl-XL similarly
inhibit pathophysiological Ca2+ overload induced by the
bile acid TLC-S in WT PACs (Fig. 5a, b). Combining these
observations we conclude that, in WT PACs the inhibi-
tion of TLC-S-induced Ca2+ release conferred by the BH4
domain peptides is mainly due to the inhibition of RyRs
and not IP3Rs.
Pharmacological inhibition of either IP3Rs or RyRs has
been shown to reduce TLC-S-induced necrosis in PACs
and the severity of AP24,25. Here we conﬁrmed this by
showing that the BH4 domains were able to inhibit TLC-S
induced necrosis (Fig. 5c). These ﬁndings underpin the
therapeutic properties of Ca2+-signaling modulation in
AP and add the BH4 domains of Bcl-2 and Bcl-XL to the
arsenal of tools with the therapeutic potential to reduce
AP burden by limiting the excessive RyR activity and cell
necrosis.
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Previous studies on the BH4 domains of the Bcl-2-family
proteins have revealed their protective properties against a
wide range of pathological stimuli17–21,31–35, particularly
with respect to the regulation of mitochondrial integrity
and thus protection from apoptosis17–21. However, whe-
ther these BH4 domains could also antagonize cell damage
by inhibiting excessive intracellular Ca2+ release, especially
aberrant RyR activity under pathological conditions, has
never been addressed. Here we show for the ﬁrst time that
these BH4 domains may provide protection in AP, a dis-
ease characterized by Ca2+-induced necrosis, via sup-
pressing excessive RyR activity (Fig. 5).
Although, the exact length of the BH4 domains used in
different studies may differ slightly, the amino acid stretch
conferring the α-helical properties in the BH4 domains
(Fig. 1a) is always present17–21,31–35. The α-helical prop-
erties of the BH4-domain peptide of Bcl-2 were previously
shown to be crucial for inhibiting both IP3R activity and
suppressing apoptosis induction, rendering this an
important feature for the biological activity of the BH4
domain of Bcl-228. In the full-length protein, the BH4
domain also contributes to the overall stability of the Bcl-
2 proteins36. PACs are known to take up small peptides
that retain their bio-activity37. Hence, in this work,
unmodiﬁed BH4-domain peptides could be applied, as
they were taken up by intact primary PACs and they
retained their biological activity (Figs. 1–5). At this point,
it remains unclear whether other cells besides PACs are
able to accumulate these unmodiﬁed peptides and whe-
ther they can be applied in vivo. An often used strategy to
improve the uptake of peptides by cells is to couple
peptides to a cell-penetrating sequence, like TAT, the
protein-transduction domain of the HIV-1 TAT pro-
tein38. Besides enhancing cell uptake, this tag also intro-
duces several positive charges, improving peptide
solubility and bio-availability. This approach has already
been used for the BH4 domain of Bcl-XL. TAT-tagged
BH4 domain of Bcl-XL retained its biological activity
when injected intravenously or intraperitonealy in mice,
protecting hearth cells from ischemia reperfusion-
induced cell death17,21, rescuing astrocyte degeneration
in amyotrophic lateral sclerosis39 and protecting neurons
from apoptosis upon frataxin depletion by restoring
proper Ca2+ homeostasis and dynamics40. Another
option/modiﬁcation for further investigating the ther-
apeutic potential of these BH4 domains is the use of
stapled BH4 domains41,42. Stapled BH4 domains are cyclic
peptides with increased stability and cell permeability.
Such tools may enable to explore the therapeutic potential
of BH4-domains of Bcl-2/Bcl-XL proteins and derivatives
in in vivo models for AP.
Taken together, we here report that the BH4-domains
of Bcl-2-family members can be utilized as peptide tools
with Ca2+-modulatory properties to reduce disease
burden in disorders such as AP. This work reveals that the
BH4 domain of Bcl-2 and Bcl-XL, or tools mimicking their
functions, may prove useful for therapeutic modulation of
the pathologies in which excessive intracellular Ca2+
release is a critical driver.
Materials and methods
Reagents, mouse strains, secondary structure prediction,
and peptides
Unless otherwise speciﬁed all reagents were obtained
from Sigma-Aldrich (Dorset, UK). Transgenic Bcl-2 KO
mice (B6;129S2-Bcl-2) were purchased from The Jackson
Laboratory. Homozygous Bcl-2 KO and the WT litter
mates were used for the experiments. All regulated animal
procedures were subject to approval by the University’s
Animal Welfare and Ethical Review Body (AWERB), and
covered by a Project Licence granted by the Home Ofﬁce
under the Animal (Scientiﬁc Procedures) Act, 1986.
PSIPRED version 3.3 (http://bioinf.cs.ucl.ac.uk/psipred/)
was utilized to predict the secondary structure of the BH4
domains of Bcl-2 and Bcl-XL.
The following peptides (purity ≥80%) were obtained
from LifeTein, validated via mass spectrometric analysis,
and dissolved in DMSO (30mM stock solution).
Control peptide: WYEKQRSLHGIMYYVIEDRNTKGYR
BH4 domain Bcl-2: RTGYDNREIVMKYIHYKLSQRG
YEW
BH4 domain Bcl-XL: MSQSNRELVVDFLSYKLSQK
GYSW
PAC isolation
Mouse PACs were isolated using a modiﬁed protocol
described in ref. 37. Brieﬂy, the pancreas of WT or Bcl-2
KO mouse was dissected and washed twice in NaHEPES
buffer (140mM NaCl, 4.8 mM KCl, 1M MgCl2, 10 mM
HEPES, 10 mM glucose and 1mM CaCl2; pH 7.2). 1 ml
collagenase (25 U/ml) (C9263) was injected into the
pancreas and then the tissue was incubated at 37 °C in a
water bath shaker. After this the pancreas was broken
down by several cycles of pipetting in 1 ml NaHEPES
buffer. The isolated PACs were spun down (200×g, 1 min),
washed with NaHEPES and then were suspended in fresh
NaHEPES.
PAC loading and single-cell Ca2+ measurements
Isolated PACs were incubated in NaHEPES containing
4 µM Fluo4-AM (Life Technologies, Loughborough, UK)
for 30min at room temperature. Then PACs were spun
down and resuspended in NaHEPES. Single-cell Ca2+
measurements were performed as indicated in the ﬁgure
descriptions, using a Scientiﬁca (East Sussex, UK) imaging
system connected to an Olympus (Cardiff, UK) IX71
microscope. In order to prevent enzymatic digestion of
the peptides, the extracellular buffer was supplemented
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with 0.2 mg/ml trypsin-chymotrypsin inhibitor. The pep-
tides and indicated stimuli were introduced to the cells
using a syringe-driven perfusion system.
Necrosis assay
Isolated PACs were treated with either vehicle (DMSO)
or the indicated peptides (50 µM) for 15 min. Then cell
death was induced by adding TLC-S (ﬁnal concentration:
200 μM) to the PACs for 2 h at room temperature. Pro-
pidium iodide (2 µg/ml; Life Technologies) was present
during the last 15 min of the TLC-S treatment. For the
peptide-treated cells, 0.2 mg/ml trypsin-chymotrypsin
inhibitor was added in order to protect the peptides
from proteolytic damage. A TCS SPE confocal micro-
scope or a multiphoton SP5 (both from Leica, Milton
Keynes, UK) were used to image the propidium iodide
staining and cell death was quantiﬁed by counting the
propidium iodide-positive cells in relation to the control.
In each experiment at least 100 cells were imaged and
counted per treatment group.
Statistical analysis
For statistical analysis GraphPad prism 7 was used.
Because of lack of normal distribution and unequal var-
iance in several tested groups, the Kruskal–Wallis test
with the Dunn’s multiple comparison post hoc test was
performed for all Ca2+ measurements. One-way ANOVA
with the Tukey’s multiple comparison post hoc tests were
performed for the necrosis assays. When using the One-
way ANOVA, the data were normally distributed and
variances were not signiﬁcantly different between the
tested groups. P-values for each statistical analysis are
given in the ﬁgure legends. *, **, *** are used to indicate
P-values <0.05, 0.01, and 0.001 between the different
groups as indicated by the post hoc test. For each
experimental setup, PACs were isolated and used inde-
pendently from at least three different mice.
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